10 October 2023
10 October 2023
A representative group for pharma companies across the UK has criticised plans to keep a growth cap on the UK branded medicines market.
The FDA CRL cited insufficient evidence to approve the use of Onpattro for treating cardiomyopathy of transthyretin mediated (ATTR) amyloidosis.
The approval marks the first intravenous (IV) formulation treatment in adults with rheumatic diseases in six years.
In a two-part column, F. Randy Vogenberg touches upon the key challenges in the employer-based US commercial insurance landscape.
The FDA decision follows a similar designation for the vaccine UV1 against malignant melanoma in December 2021.
Theramex has added the synthetic hormones to its portfolio as Viatris divests its businesses and sells assets.
The Series A funds will help advance a pipeline, which includes drugs that provide both symptomatic and disease-modifying benefits.
IPD and Biovac will each receive a $5m grant to acquire the technology to develop locally relevant vaccines.
Join us on October 17th, as Boris Baňas and Jan Storch discuss the challenges of sourcing certified cannabis for clinical trials and delve into CB21 Pharma's cannabis-derived product portfolio.
As PD therapy currently centers on symptomatic treatment, the need for DMTs is one of the greatest unmet needs. Several companies within the late-stage PD pipeline are developing drugs that target PD via novel MOAs. KOLs remain hopeful that these companies will uncover a class of drugs that works effectively to slow or modify the disease course. Targeting α-synuclein and other neurotoxic proteins is a key strategy in the late-stage pipeline for DMTs.
Give your business an edge with our leading industry insights.
